US20170172964A1 - Composition for Treatment of Skin - Google Patents

Composition for Treatment of Skin Download PDF

Info

Publication number
US20170172964A1
US20170172964A1 US15/222,773 US201615222773A US2017172964A1 US 20170172964 A1 US20170172964 A1 US 20170172964A1 US 201615222773 A US201615222773 A US 201615222773A US 2017172964 A1 US2017172964 A1 US 2017172964A1
Authority
US
United States
Prior art keywords
composition
oil
acid
skin
collagen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/222,773
Inventor
Keith Coupland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SEEDS GROUP LP
Original Assignee
SEEDS GROUP LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SEEDS GROUP LP filed Critical SEEDS GROUP LP
Priority to US15/222,773 priority Critical patent/US20170172964A1/en
Assigned to SEEDS GROUP, LP reassignment SEEDS GROUP, LP ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COUPLAND, KEITH
Publication of US20170172964A1 publication Critical patent/US20170172964A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
    • A61K47/48046—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to a composition for topical application to the human or animal body.
  • it relates to compositions containing naturally occurring plant seed oils to stimulate collagen synthesis in skin cells.
  • Such compositions are useful in the treatment of skin and in wound healing.
  • Most plant seed oils are triglyceride esters of fatty acids and glycerol.
  • the fatty acids may be saturated, mono-unsaturated or poly-unsaturated.
  • the plant seed oils that are of value in the treatment of skin conditions, by stimulating collagen production in skin cells are those containing poly-unsaturated fatty acids.
  • Fatty acids are aliphatic monocarboxylic acids which occur naturally in animal or vegetable fats or oils in the form of esters particularly triglyceride esters. Because of their perceived usefulness in for example human nutrition, a great deal of effort has been put into extracting triglyceride esters containing poly-unsaturated fatty acids from their natural sources.
  • Stearidonic acid is a polyunsaturated fatty acid of the n3 family which is described in the conventional nomenclature as C18:4n3. It can be found in the form of a triester of glycerol (or triglyceride) in the oils of blackcurrant, redcurrant and gooseberry pips.
  • WO 97/46220 discloses that SDA triglyceride can be sourced from oil extracted from the seeds of the Boraginaceae plant family and that the oil itself can be used in dietetic, cosmetic and healthcare products, without the need for additional treatment or purification.
  • a particularly rich source of SDA is the seeds of the genus Echium.
  • U.S. Pat. No. 6,340,485 discloses a composition comprising from 1 to 20% by weight of an oil extracted from the seeds of Boraginaceae plant species (particularly the Echium species) comprising from 5 to 20 SDA triglyceride and 80 to 95% of other fatty acid triglycerides.
  • the composition is said to be particularly suited for oral or topical administration and for dietary, cosmetic, pharmaceutical and healthcare use.
  • the composition is said to be especially advantageous for use in treating skin inflammation and particularly sunburn.
  • Echium oil in compositions for treating skin, for example: WO 2008/00074 A2 (L'Occitane); US 2008/0213357 A1 (Hebard); and WO 02/092073 A1 (Martek Biosciences Boulder Corporation).
  • a composition comprising the active ingredients of Echium oil is also disclosed in EP 0 460 848 A1 (Efamol Holdings Plc.).
  • An exemplary composition comprises extracts of rosemary, marigold, sage, ginseng , St. John's wart and ruscus as active ingredients.
  • Marigold extract is also disclosed as an active ingredient in cosmetic compositions to fight against the signs of skin aging in the following prior art references: FR 2902334 A1 (Laboratoire Nuxe); JP 2001253817 A (Nagase); and WO 2004/022034 A1 (Dermaphyt).
  • RO 118256 B discloses an anti-wrinkle cosmetic cream comprising inter alia an extract from the leaves and flowering stalks of Calendula .
  • Oil such as peanut oil
  • the composition comprises Calendula oil in the sense of an oil produced from Calendula seeds.
  • Skin aging is the result of two distinct processes; extrinsic (caused by environmental factors such as UVA/UVB exposure, lifestyle, tobacco smoking, excessive alcohol intake and diet) and intrinsic or chronological aging where genetic factors are involved.
  • extrinsic caused by environmental factors such as UVA/UVB exposure, lifestyle, tobacco smoking, excessive alcohol intake and diet
  • intrinsic or chronological aging where genetic factors are involved.
  • the visible result of skin aging is loss of skin tone and elasticity, dehydration, skin roughness, age spots, lines and wrinkles. It is known that a major factor involved in the production of skin sagging, lines and wrinkles is the chronological reduction in skin collagen.
  • environmental factors can stimulate the production of proteolytic enzymes involved in collagen breakdown.
  • composition for topical application to the human or animal body comprising stearidonic acid, or an ester thereof, and an additional lipid which enhances the pro-collagen effects of stearidonic acid.
  • said additional lipid is a conjugated octadecatrienoic acid (CODTA) or an ester thereof.
  • CODTA conjugated octadecatrienoic acid
  • the stearidonic acid is provided by oil extracted from the seeds of the Boraginaceae plant family, and most preferably from the Echium species Echium plantagineum .
  • the oil may be present in an amount from 0.1% to 10% w/w, preferably about 4.95% w/w.
  • the additional lipid is preferably present is an amount from 0.005% to 1% w/w, more preferably from 0.01% to 0.1% w/w, most preferably about 0.05% w/w.
  • compositions of the present invention may also comprise a physiologically acceptable carrier.
  • a physiologically acceptable carrier may additionally comprise one or more of a moisturiser, an emollient, an emulsifier, a preservative, a dispersant, a viscosity modifier, a herbal extract, a solvent, a chelating agent, an antioxidant, vitamin C, an ester of vitamin C, ascorbyl palmitate, magnesium ascorbyl phosphate, a water-proofing agent, a pH adjuster, a perfume, and an aminoacid, peptide or protein.
  • compositions may be formulated as solids, liquids, aerosols, creams, emulsions, gels or in capsule form.
  • a method of reducing visible signs of aging of human or animal skin comprising applying to said skin any of said compositions as defined above in combination with a physiologically acceptable carrier.
  • a method of healing wounds in a human or animal body comprising applying to the locus of the wound any of said compositions as defined above in combination with a physiologically acceptable carrier.
  • a composition comprising stearidonic acid (preferably provided in the form of Echium oil) or calendula oil or a mixture thereof for use in the stimulation of collagen synthesis in skin cells.
  • stearidonic acid preferably provided in the form of Echium oil
  • calendula oil or a mixture thereof for use in the stimulation of collagen synthesis in skin cells.
  • the surprising realisation of the present applicant is that Echium oil and calendula oil act alone (or in combination) to stimulate collagen synthesis in skin cells. Previously, this mechanism of action has not been known.
  • the result of this inventive realisation is that the composition can be used as cosmetic products and also as components in wound dressings to accelerate wound healing.
  • the active ingredient is calendula oil and not calendula extract as employed in the prior art.
  • the extract is a decoction of calendula flowers (usually in a vegetable oil such as sunflower seed oil or peanut oil) whereas the oil may be produced by grinding up the seeds of the Calendula plant and extracting the diminuted seed with a suitable solvent such as hexane or super critical carbon dioxide. Alternatively the oil may be obtained by simply cold pressing the Calendula seeds. Calendula extract does not contain calendic acid whereas calendula oil does.
  • composition comprising stearidonic acid (preferably provided in the form of Echium oil) for use in the reduction of trans-epidermal water loss.
  • composition comprising stearidonic acid (preferably provided in the form of Echium oil) for use in the reduction of skin wrinkles.
  • FIG. 1 is a diagram showing the EST-1000 epidermis model
  • FIG. 2 is a bar graph showing the effect of various oils on collagen 1 gene expression
  • FIG. 3 is a bar graph showing the effect of various oils on collagen 1 and collagen 4 gene expression
  • FIG. 4 is a bar graph showing the effect of various formulated products on collagen 1 and collagen 4 gene expression
  • FIG. 5 is a bar graph showing the effect of various test oils on collagen 3 gene expression.
  • FIG. 6 is a bar graph showing the effect of various formulated products on collagen 3 gene expression.
  • phase A Combine all ingredients of phase A, add phase B to phase A with stirring at 70 Deg C. Allow to cool to 40 Deg C and add phase C with stirring. Adjust pH, if necessary, with dilute aqueous sodium hydroxide solution.
  • the in vitro data on collagen synthesis from skin cells were obtained using the following experimental method.
  • Human fibroblasts or keratinocytes were seeded into 24-well plates and cultured in normal media until approximately 50% confluent.
  • Test solutions Echium oil, Calendula oil or mixtures of the two oils
  • DMSO dimethyl sulphoxide
  • the concentrated oil solutions were serially diluted with normal media with sonification (5 minutes) before adding to the cells.
  • the concentration of oils in media was 0.00001%, 0.0001%, or 0.001%.
  • Fibroblasts and keratinocytes were cultured with the oils for 3 days or 7 days (with a change of media containing oils at day 3 for 7 day cultures).
  • the cells were fixed by addition of formaldehyde solution (3.7%) followed by washing three times with phosphate buffered saline (PBS).
  • PBS phosphate buffered saline
  • Sirius red in picric acid 0.1%) was added to the wells for approximately 18 hours. Unbound dye was removed and wells washed with tap water until clear. Following drying the dye was eluted with “Destain” (0.2M NaOH in methanol 1:1) for 15 min with gentle shaking. The optical density of the eluates were measured (490 nm) using a plate reader.
  • both test oils increased collagen synthesis by between 21.7%-30.0%.
  • both oils again increased collagen synthesis ( Calendula oil—27.2%, Echium oil—16.0%).
  • a home-use study was carried out on 22 female subjects over a six week period.
  • Trans-epidermal water-loss (TEWL) measurements and skin impressions were taken at baseline and at the end of the six week usage period.
  • a consumer perception questionnaire was also completed by all subjects after the six weeks of use. The aim of the study was to determine if the test material, a facial skin serum F1/1445D, was effective in reducing fine lines and wrinkles.
  • Skin Serum F1/1445D is a composition including 5% w/w Echium oil having the following formulation (all amounts are in % w/w):
  • Profilometry and TEWL assessments were available for 22 volunteers. Readings were taken at Baseline and Week 6. The treatment was applied to the face twice daily for 6 weeks, morning and night. Casts of the skin surface and evaporimeter readings were taken from the temple area of each side of the face at Baseline and Week 6.
  • the primary endpoints for analysis were the changes from Baseline (pre-treatment) to Week 6 (post treatment) for each roughness parameter assessment (Sa, Sq, Sp, Sv, St, and Sz), obtained from the profilometer.
  • the change from Baseline to Week 6 for each roughness parameter was subjected to parametric analysis of covariance (ANCOVA) techniques using SAS procedure PRC MIXED.
  • the ANCOVA tested the null hypothesis that the changes from Baseline to Week 6 were equal to zero.
  • the model included terms for side (left or right temple area) and Baseline value, with subject as a random effect.
  • the secondary endpoint change from Baseline to Week 6 for TEWL, was analysed using the same technique as for the primary endpoints.
  • the adjusted mean changes from Baseline to Week 6 the corresponding 95% confidence intervals and p-values are presented for each roughness parameter separately by side (using the same ANCOVA model as detailed above), as there was a noticeable difference in the mean change from baseline values between the left and right temple areas for all roughness parameters.
  • Table 1 presents the results for the roughness and TEWL parameters analysed. All roughness parameters had a statistically significant reduction from Baseline to Week 6 for TEWL, there was also found to be a statistically significant reduction from Baseline to Week 6.
  • Lipid formulations were applied topically on EST-1000 epidermis models (Cellsystems Biotechnologiemaschinemaschine GmbH) as shown in FIG. 1 .
  • the models consist of primary human keratinocytes and exhibit a physiological differentiation pattern throughout the epidermal layers consisting of a basal cell layer ( stratum basale ), spinous (or prickle) cell layer ( stratum spinosum ), granular layer ( stratum granulosum ) and finally the cornified layer ( stratum corneum ).
  • the cornified layer is responsible for the characteristic barrier capacity of the epidermis.
  • the barrier function is used as the main quality control.
  • the EST-1000 models are usually cultivated for 14 days at airlift conditions. To facilitate a longer time of treatment and observation skin models of 11 day airlift culture were used throughout this study.
  • the protocol and detection system for the analyses of collagen I protein were tested using an EST-1000 model each.
  • the skin model was untreated.
  • Collagen protein was secreted into the extracellular matrix (ECM). Therefore, the protein has to be extracted from the ECM.
  • the extraction protocol involves the treatment of the skin model by pepsin and elastase.
  • the concentration of the protein fragments released by the extraction was measured by ELISA and correlated directly to the collagen content.
  • the pH in the combined supernatant in the collection tubes are neutralised by adding 1 M Tris buffer (1/50 of the volume of the supernatants).
  • the above described collagen extraction protocol is adapted from the collagen I extraction protocol described in the manual of the collagen I detection kit (Chondrex Inc. #6008).
  • RNA preparation The expression of the genes coding for collagen I was analysed by RT-PCR (reverse transcriptase polymerase chain reaction) using the Taqman gene expression assays (Applied Biosystems).
  • the ESTs were cut from the inserts as described above.
  • the cut ESTs were stored in RNAlater (Ambion) at 4° C. until RNA preparation.
  • RNA preparation the tissue was disintegrated using the Precellys (Peqlab Biotechnologie GmbH, Germany).
  • the cells were lysed in RLT buffer (RNeasy-kit, Qiagen). The RNA was purified from these lysates by three different protocols:
  • RNA could be isolated also from the treated ESTs).
  • RNAs analysed by RT-PCR were purified by chloroform extraction.
  • the expression of the collagen I gene was induced by all treatments (see FIG. 2 ). In particular, a relatively high fold change was observed for Echium oil in combination with Calendula oil and for Echium oil in combination with pomegranate seed oil.
  • test oils containing Echium oil and Calendula oil were evaluated in the EST 1000TMskin model (3) .
  • the test oil used was glyceryl tricaprylate/caprate (Crodamol GTCC, or MCI) to act as an inert carrier oil.
  • the overall objective was to confirm earlier results showing that Echium/Calendula oil mixtures were synergistic in promoting collagen synthesis in skin.
  • a number of genes involved in collagen synthesis in skin cells were analyzed using the reverse transcription-polymerase chain reaction (RT-PCR).
  • the experimental lotions (referred to as Seeds #2 and Seeds #3 in Table III below) have the following composition:
  • EST1000 20 ⁇ L of the test oils were applied on the surface of the EST1000 in triplicates. After application the ESTs were incubated over night (18 h) at 37° C., 5% CO 2 and 100% humidity. The visibility of EST1000 was measure by MTT-test.
  • RNAlater Analog to RNA preparation. The RNA was prepared and the concentration and quality of the isolated RNA was controlled. The quality is determined by the ratio between the optical densities of the RNA at 260 and 280 nm. A ratio of more or equal 1.8 represents a good quality of RNA.
  • the viability of EST1000 was measured by the MTT-test which is based on the reduction of 3-4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid (MTT) by the mitochondrial reductases.
  • MTT 3-4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid
  • the reduction of MTT leads to the formation of purple formazan crystals which are solved in isopropanol.
  • the amount of formazan can be measured at 550 nm and correlates directly with the viability.
  • the viability of the treated epidermis models is calculated as percentage of the non treated controls which are defined as 100%.
  • RT-PCR analyses were performed according to the Applied Biosystems protocol (Taqman). In short: 1 ⁇ g of the RNA was transcribed to cDNA which was used as template for the real-time RT-PCR with gene specific primers and probes.

Abstract

The present invention provides a composition comprising stearidonic acid (or an ester thereof) derived for example from Echium oil, and an additional lipid (derived for example from calendula oil) which enhances the pro-collagen effects of stearidonic acid. The composition is useful in reducing visible signs of aging of human or animal skin or a method of wound healing.

Description

  • The present invention relates to a composition for topical application to the human or animal body. In particular, it relates to compositions containing naturally occurring plant seed oils to stimulate collagen synthesis in skin cells. Such compositions are useful in the treatment of skin and in wound healing.
  • Most plant seed oils (lipids) are triglyceride esters of fatty acids and glycerol. The fatty acids may be saturated, mono-unsaturated or poly-unsaturated. The plant seed oils that are of value in the treatment of skin conditions, by stimulating collagen production in skin cells, are those containing poly-unsaturated fatty acids.
  • Fatty acids are aliphatic monocarboxylic acids which occur naturally in animal or vegetable fats or oils in the form of esters particularly triglyceride esters. Because of their perceived usefulness in for example human nutrition, a great deal of effort has been put into extracting triglyceride esters containing poly-unsaturated fatty acids from their natural sources.
  • Stearidonic acid (SDA) is a polyunsaturated fatty acid of the n3 family which is described in the conventional nomenclature as C18:4n3. It can be found in the form of a triester of glycerol (or triglyceride) in the oils of blackcurrant, redcurrant and gooseberry pips. WO 97/46220 (Croda International Plc) discloses that SDA triglyceride can be sourced from oil extracted from the seeds of the Boraginaceae plant family and that the oil itself can be used in dietetic, cosmetic and healthcare products, without the need for additional treatment or purification. A particularly rich source of SDA is the seeds of the genus Echium.
  • U.S. Pat. No. 6,340,485 (Croda International Plc) discloses a composition comprising from 1 to 20% by weight of an oil extracted from the seeds of Boraginaceae plant species (particularly the Echium species) comprising from 5 to 20 SDA triglyceride and 80 to 95% of other fatty acid triglycerides. The composition is said to be particularly suited for oral or topical administration and for dietary, cosmetic, pharmaceutical and healthcare use. In particular, the composition is said to be especially advantageous for use in treating skin inflammation and particularly sunburn. Although it is admitted that the pathogenesis of sunburn is not completely understood, it is postulated that the release of inflammatory mediators including eicosanoids and cytokines (which can be metabolised from SDA) seems to be important.
  • A number of other prior art references disclose the use of Echium oil in compositions for treating skin, for example: WO 2008/00074 A2 (L'Occitane); US 2008/0213357 A1 (Hebard); and WO 02/092073 A1 (Martek Biosciences Boulder Corporation). A composition comprising the active ingredients of Echium oil (stearidonic acid and gamma-linolenic acid) is also disclosed in EP 0 460 848 A1 (Efamol Holdings Plc.).
  • US 2004/0161435 A1 (Gupta) discloses a cosmetic mask composition which promotes excess fat reduction, cellulite control or muscle and skin toning benefits.
  • An exemplary composition comprises extracts of rosemary, marigold, sage, ginseng, St. John's wart and ruscus as active ingredients.
  • Marigold extract is also disclosed as an active ingredient in cosmetic compositions to fight against the signs of skin aging in the following prior art references: FR 2902334 A1 (Laboratoire Nuxe); JP 2001253817 A (Nagase); and WO 2004/022034 A1 (Dermaphyt).
  • RO 118256 B (Farmec SA) discloses an anti-wrinkle cosmetic cream comprising inter alia an extract from the leaves and flowering stalks of Calendula. Oil (such as peanut oil) is used for the extraction, but it is not believed that the composition comprises Calendula oil in the sense of an oil produced from Calendula seeds.
  • Skin aging is the result of two distinct processes; extrinsic (caused by environmental factors such as UVA/UVB exposure, lifestyle, tobacco smoking, excessive alcohol intake and diet) and intrinsic or chronological aging where genetic factors are involved. The visible result of skin aging is loss of skin tone and elasticity, dehydration, skin roughness, age spots, lines and wrinkles. It is known that a major factor involved in the production of skin sagging, lines and wrinkles is the chronological reduction in skin collagen. In addition environmental factors can stimulate the production of proteolytic enzymes involved in collagen breakdown.
  • In a first aspect of the present invention there is provided a composition for topical application to the human or animal body comprising stearidonic acid, or an ester thereof, and an additional lipid which enhances the pro-collagen effects of stearidonic acid.
  • In a preferred embodiment said additional lipid is a conjugated octadecatrienoic acid (CODTA) or an ester thereof. The best known naturally occurring CODTAs are tabulated below:
  • CODTA Configuration Source
    Calendic acid 8t10t12c-18:3 Calendula officinalis
    Catalpic acid 9t11t13c-18:3 Catalpa ovata
    α-Eleostearic acid 9c11t13t-18:3 Aleurites fordii
    Jacaric acid 8c10t12c-18:3 Jacaranda mimosifolia
    Punicic acid 9c11t13c-18:3 Punica granatum
  • Preferably, the stearidonic acid is provided by oil extracted from the seeds of the Boraginaceae plant family, and most preferably from the Echium species Echium plantagineum. The oil may be present in an amount from 0.1% to 10% w/w, preferably about 4.95% w/w.
  • The additional lipid is preferably present is an amount from 0.005% to 1% w/w, more preferably from 0.01% to 0.1% w/w, most preferably about 0.05% w/w.
  • The compositions of the present invention may also comprise a physiologically acceptable carrier. For example, they may additionally comprise one or more of a moisturiser, an emollient, an emulsifier, a preservative, a dispersant, a viscosity modifier, a herbal extract, a solvent, a chelating agent, an antioxidant, vitamin C, an ester of vitamin C, ascorbyl palmitate, magnesium ascorbyl phosphate, a water-proofing agent, a pH adjuster, a perfume, and an aminoacid, peptide or protein.
  • The compositions may be formulated as solids, liquids, aerosols, creams, emulsions, gels or in capsule form.
  • In a second aspect of the invention there is provided a method of reducing visible signs of aging of human or animal skin comprising applying to said skin any of said compositions as defined above in combination with a physiologically acceptable carrier.
  • In a third aspect of the invention there is provided a method of healing wounds in a human or animal body comprising applying to the locus of the wound any of said compositions as defined above in combination with a physiologically acceptable carrier.
  • In accordance with a fourth aspect of the present invention, there is provided a composition comprising stearidonic acid (preferably provided in the form of Echium oil) or calendula oil or a mixture thereof for use in the stimulation of collagen synthesis in skin cells.
  • The surprising realisation of the present applicant is that Echium oil and calendula oil act alone (or in combination) to stimulate collagen synthesis in skin cells. Previously, this mechanism of action has not been known. The result of this inventive realisation is that the composition can be used as cosmetic products and also as components in wound dressings to accelerate wound healing.
  • It is important to note that the active ingredient is calendula oil and not calendula extract as employed in the prior art. The extract is a decoction of calendula flowers (usually in a vegetable oil such as sunflower seed oil or peanut oil) whereas the oil may be produced by grinding up the seeds of the Calendula plant and extracting the diminuted seed with a suitable solvent such as hexane or super critical carbon dioxide. Alternatively the oil may be obtained by simply cold pressing the Calendula seeds. Calendula extract does not contain calendic acid whereas calendula oil does.
  • In accordance with a further aspect of the present invention, there is provided a composition comprising stearidonic acid (preferably provided in the form of Echium oil) for use in the reduction of trans-epidermal water loss.
  • In accordance with yet a further aspect of the present invention, there is provided a composition comprising stearidonic acid (preferably provided in the form of Echium oil) for use in the reduction of skin wrinkles.
  • A number of preferred embodiments of the invention will now be described with reference to the following drawings, in which:
  • FIG. 1 is a diagram showing the EST-1000 epidermis model;
  • FIG. 2 is a bar graph showing the effect of various oils on collagen 1 gene expression;
  • FIG. 3 is a bar graph showing the effect of various oils on collagen 1 and collagen 4 gene expression;
  • FIG. 4 is a bar graph showing the effect of various formulated products on collagen 1 and collagen 4 gene expression;
  • FIG. 5 is a bar graph showing the effect of various test oils on collagen 3 gene expression; and
  • FIG. 6 is a bar graph showing the effect of various formulated products on collagen 3 gene expression.
    •  EXAMPLES
  • A] Formulations with Echium oil
  • 1. Moisturizing Lotion
  • % by weight
    Caprylic/Capric Triglyceride 8.0
    Nonionic Emulsifying Wax 2.5
    Cetearyl Alcohol 1.0
    Glyceryl Stearate non-emulsifiable (N/E) 1.5
    Echium Oil 1.0-4.0
    Water to 100
    Carbomer - Carbopol 981 2% solution (BF Goodrich) 10.0
    Glycerine 2.0
    Triethanolamine to pH 6.5-7.0
    Perfume, Preservative, Colour qs
  • Method
  • Heat oil phase and water phase separately to 65-70 Deg C. Add water phase to oil phase with stirring and cool. Add perfume, preservatives, colour and optional ingredients e.g. plant extracts at 35 Deg C.
  • 2. Anti-Wrinkle Night Cream
  •
    Phase A
    Ceteareth-25 2.0
    Ceteareth-6/Steatyl Alcohol 2.0
    Mineral Oil 8.0
    Cetearyl Ethylhexanoate 7.0
    Glyceryl Stearate 6.0
    Cetyl Alcohol 1.0
    Echium oil 1.0-5.0
    Phase B
    Water to 100
    Panthenol, Propylene Glycol 1.0
    Propylene Glycol 3.0
    Sodium Lactate 5.0
    Perfume, Preservative qs
    Phase C
    Caprylic/Capric Triglyceride, Acrylates Copolymer 1.3
  • Method
  • Heat phases A and B separately to about 80 Deg C. Stir phase B into phase A and homogenize. Add phase C with stirring to phase A+B and homogenize. Cool to 40 Deg C.
  • 3. Light Day Cream
  •
    Dioctyl Succinate 6.0
    Glyceryl Stearate, PEG100 4.0
    Nonionic Emulsifying Wax GP200 4.0
    Echium Oil 40-8.0
    Water to 100
    Carbomer (Carbopol 981, 2% aqueous solution) 10.0 
    Perfume, Preservative, Colour qs
  • Method
  • Heat oil and water phases separately to 65-70 Deg C. Add water phase to oil phase with stirring. Stir to cool adjusting pH to about 7 with triethanolamine at 60 Deg C.
  • 4. Deep Wrinkle Treatment
  •
    Phase A
    Cetearyl Alcohol, Dicetyl Phosphate, Ceteth10 Phosphate 5.0
    Cetyl Alcohol  0.25
    PPG-3 Benzyl Ether Myristate 5.0
    Echium Oil 3.0
    Phase B
    Water to 100
    Phase C
    Glycerine, Water, Butylene Glycol, Carbomer, Polysorbate-20, 4.0
    Palmitoyl Oligopeptide, Palmitoyl Tetrapeptide-3
    Perfume, Preservative, Colour qs
  • Method
  • Combine all ingredients of phase A, add phase B to phase A with stirring at 70 Deg C. Allow to cool to 40 Deg C and add phase C with stirring. Adjust pH, if necessary, with dilute aqueous sodium hydroxide solution.
  • B] Lipid Compositions Useful for Increasing Collagen Synthesis in Skin Cells
  • The in vitro data on collagen synthesis from skin cells (either fibroblasts or keratinocytes) were obtained using the following experimental method. Human fibroblasts or keratinocytes were seeded into 24-well plates and cultured in normal media until approximately 50% confluent. Test solutions (Echium oil, Calendula oil or mixtures of the two oils) were initially prepared at 1% in dimethyl sulphoxide (DMSO) with sonification for 5 minutes. The concentrated oil solutions were serially diluted with normal media with sonification (5 minutes) before adding to the cells. The concentration of oils in media was 0.00001%, 0.0001%, or 0.001%.
  • Fibroblasts and keratinocytes were cultured with the oils for 3 days or 7 days (with a change of media containing oils at day 3 for 7 day cultures). The cells were fixed by addition of formaldehyde solution (3.7%) followed by washing three times with phosphate buffered saline (PBS). The collagen specific dye; Sirius red in picric acid (0.1%) was added to the wells for approximately 18 hours. Unbound dye was removed and wells washed with tap water until clear. Following drying the dye was eluted with “Destain” (0.2M NaOH in methanol 1:1) for 15 min with gentle shaking. The optical density of the eluates were measured (490 nm) using a plate reader.
  • Results
    • Collagen Production (Optical Density/490 nm) from Fibroblasts Following Incubation (3 Days) with Test Oils and DMSO Control
  • 0.00001% 0.0001% 0.001%
    Calendula Calendula Calendula
    oil Echium oil DMSO oil Echium oil DMSO oil Echium oil DMSO
    0.1460 0.1560 0.1200 0.1580 0.1580 0.1240 0.1440 0.1460 0.1160
    21.7% 30.0% 27.4% 27.4% 24.1% 25.9%
    • Collagen Production (Optical Density/490 nm) from Keratinocytes Following Incubation (3 Days) with Test Oils and DMSO Control
  • 0.00001% 0.0001% 0.001%
    Calendula Echium Calendula Echium Calendula Echium
    oil oil DMSO oil oil DMSO oil oil DMSO
    0.5365 0.4896 0.4219 0.5052 0.4635 0.4375 0.4688 0.4792 0.4427
    27.2% 16.0% 15.5% 5.9% 5.9% 8.2%
  • As can be seen in fibroblasts both test oils increased collagen synthesis by between 21.7%-30.0%. In keratinocytes the effect was less marked however at low concentrations both oils again increased collagen synthesis (Calendula oil—27.2%, Echium oil—16.0%).
    • C] Profilometry Study to Determine the Efficacy of a Cosmetic Skin Serum in Reducing Fine Lines and Wrinkles
  • A home-use study was carried out on 22 female subjects over a six week period. Trans-epidermal water-loss (TEWL) measurements and skin impressions were taken at baseline and at the end of the six week usage period. A consumer perception questionnaire was also completed by all subjects after the six weeks of use. The aim of the study was to determine if the test material, a facial skin serum F1/1445D, was effective in reducing fine lines and wrinkles.
  • Skin Serum F1/1445D is a composition including 5% w/w Echium oil having the following formulation (all amounts are in % w/w):
  •
    WATER DEIONISED 66.61
    ALLANTOIN 0.10
    AMIGEL GRANULATED 0.30
    PHYTIC ACID 0.02
    XANTHUM GUM 0.30
    LACTIGLUTAMMATO 3.00
    SODIUM HYALURONATE 100% 0.06
    LACTIC ACID 0.01
    FUCOGEL 100 5.00
    ACTISEA 100 5.00
    DL ALPHA TOCOPHEROL 0.50
    AVOCADOL 2.00
    BIOPHILLIC S 2.00
    TEGOCARE 450 0.50
    ECHIUM OIL 5.00
    ACTIPHYTE OF GOTU KOLA 2.00
    WITCH HAZEL BPC DIST. 2.00
    Pimpinella Anisum (Anise) Fruit Extract 2.00
    Prunus Amygdalus Dulcis 2.00
    (Sweet Almond Seed Extract)
    LIPOSYS.COMP.VITAMIN A&E 0.5
    EUXYL K702 0.60
    K/62277 ROSEBUD FRAG. 0.50
  • Result
  • The comments given by the subjects were generally positive. However, the fragrance of the serum was disliked by the majority of the panel.
  • Statistical Report
  • 1. Methodology
  • The Medical Data Sciences Department at Inveresk, a Charles River Company, performed the statistical analysis. The statistics package SAS (v8.2) was used to perform the statistical analyses.
  • Profilometry and TEWL assessments were available for 22 volunteers. Readings were taken at Baseline and Week 6. The treatment was applied to the face twice daily for 6 weeks, morning and night. Casts of the skin surface and evaporimeter readings were taken from the temple area of each side of the face at Baseline and Week 6.
  • 1.1 Statistical Methods Planned in Protocol
  • The primary endpoints for analysis were the changes from Baseline (pre-treatment) to Week 6 (post treatment) for each roughness parameter assessment (Sa, Sq, Sp, Sv, St, and Sz), obtained from the profilometer.
  • The change from Baseline to Week 6 for each roughness parameter was subjected to parametric analysis of covariance (ANCOVA) techniques using SAS procedure PRC MIXED. The ANCOVA tested the null hypothesis that the changes from Baseline to Week 6 were equal to zero. The model included terms for side (left or right temple area) and Baseline value, with subject as a random effect. The adjusted mean changes from Baseline to Week 6, the corresponding 95% confidence intervals and p-values are presented for each roughness parameter.
  • Exploratory analysis was undertaken to assess the influence of outliers. If assumptions for a normal distribution remained doubtful, a corresponding non-parametric approach (i.e. a generalised Wilcoxon test, applying the ranked response variable to the above analysis) was to be used.
  • The secondary endpoint, change from Baseline to Week 6 for TEWL, was analysed using the same technique as for the primary endpoints.
  • 1.2 Changes from Planned Methods
  • Additionally, the adjusted mean changes from Baseline to Week 6, the corresponding 95% confidence intervals and p-values are presented for each roughness parameter separately by side (using the same ANCOVA model as detailed above), as there was a noticeable difference in the mean change from baseline values between the left and right temple areas for all roughness parameters.
  • 2. Results for Week 6 Change from Baseline
  • 2.1 Change from Baseline
  • TABLE I
    Statistical Analysis of Profilometry and TEWL Parameters
    Post treatment
    Change from Lower 95% Upper 95%
    Parameter Baseline CI CI P-value
    Sa (μm) −4.3 −6.7 −1.9 0.001
    SA (μm)* −4.9 −7.0 −2.8 <0.001
    Sq (μm) −5.9 −9.2 −2.6 0.001
    Sq (μm)* −6.8 −9.7 −3.8 <0.001
    Sp (μm) −37.9 −58.5 −17.3 <0.001
    Sv (μm) −29.5 −57.6 −1.5 0.040
    Sv (μm)* −36.6 −59.2 −14.1 0.003
    St (μm) −67.4 −103.7 −31.2 <0.001
    Sz (μm) −57.5 −79.6 −35.5 <0.001
    TEWL −2.8 −3.8 −1.9 <0.001
    (g/cm2/h)
    *results after removing extreme observation
  • Table 1 presents the results for the roughness and TEWL parameters analysed. All roughness parameters had a statistically significant reduction from Baseline to Week 6 for TEWL, there was also found to be a statistically significant reduction from Baseline to Week 6.
  • The assumption of normality was satisfied for parameters Sp, St, Sz and TEWL. For the remaining parameters Sa, Sq, and Sz there was evidence of one outlier in each analysis (Panel no. 19672, right side for Sa and Sq, and panel no. 20271, left side for Sv). A secondary analysis was undertaken with the removal of the relevant outliers and the normality assumption was satisfied following the removal of outliers.
  • 3. Results for Week 6 Change from Baseline by Side
  • 3.1 Change from Baseline by Side
  • There was a noticeable difference in the mean change from baseline values between the left and right temple areas for all roughness parameters. The mean difference between values from the left and right side even reached statistical significance at the 5% level for parameters Sa, Sq and Sz. Therefore Table II presents the results for the left and right temple areas separately for all roughness and TEWL parameters analysed.
  • TABLE II
    Statistical Analysis of Profilometry and TEWL Parameters by Side
    Post
    treatment
    Change
    Temple from Lower Upper
    Parameter Area Baseline 95% CI 95% CI P-value
    Sa (μm) Left −6.7 −9.7 −3.6 <0.001
    Left* −6.7 −9.3 −4.1 <0.001
    Right −2.0 −5.0 1.1 0.20
    Right* −3.1 −5.8 −0.4 0.024
    Sq (μm) Left −9.4 −13.6 −5.1 <0.001
    Left* −9.5 −13.0 −5.9 <0.001
    Right −2.4 −6.7 1.8 0.25
    Right* −4.1 −7.7 −0.4 0.029
    SP (μm) Left −50.8 −80.0 −21.6 0.001
    Right −25.0 −54.2 4.2 0.092
    Sv (μm) Left −42.7 −81.2 −4.1 0.031
    Left* −57.6 −89.0 −26.2 <0.001
    Right −16.4 −55.0 22.1 0.39
    Right* −15.6 −46.3 15.0 0.31
    St (μm) Left −98.0 −148.3 −47.8 <0.001
    Right −36.9 −87.1 13.4 0.15
    Sz (μm) Left −87.8 −115.6 −59.9 <0.001
    Right −27.3 −55.2 0.6 0.055
    TEWL Left −3.1 −4.1 −2.1 <0.001
    (g/cm2/h)
    Right −2.6 −3.6 −1.6 <0.001
    *results after removing extreme observation
  • All roughness parameters had a statistically significant reduction from Baseline to Week 6 for the left temple area, however this reduction was not found to be significant for the right temple area for any of the roughness parameters. For TEWL, there was found to be a statistically significant reduction from baseline to Week 6 for both temple areas.
  • The assumption of normality was satisfied for parameters Sp, St, Sz and TEWL. For the remaining parameters Sa, Sq and Sz there was evidence of one outlier in each analysis (Panel no. 19672, right side for Sa and Sq, and panel no. 20271, left side for Sv). A secondary analysis was undertaken with the removal of the relevant outliers, and the normality assumption was satisfied following the removal of outliers.
  • D] Analyses of the Effects of Lipid Formulations on Collagen 1 Content
  • Protocol
  • Lipid formulations were applied topically on EST-1000 epidermis models (Cellsystems Biotechnologie Vertrieb GmbH) as shown in FIG. 1. The models consist of primary human keratinocytes and exhibit a physiological differentiation pattern throughout the epidermal layers consisting of a basal cell layer (stratum basale), spinous (or prickle) cell layer (stratum spinosum), granular layer (stratum granulosum) and finally the cornified layer (stratum corneum). The cornified layer is responsible for the characteristic barrier capacity of the epidermis. The barrier function is used as the main quality control. The EST-1000 models are usually cultivated for 14 days at airlift conditions. To facilitate a longer time of treatment and observation skin models of 11 day airlift culture were used throughout this study.
  • Pre-Experimental Run Testing Collagen I ELISA
  • Before the start of the study, the protocol and detection system for the analyses of collagen I protein were tested using an EST-1000 model each. The skin model was untreated. Collagen protein was secreted into the extracellular matrix (ECM). Therefore, the protein has to be extracted from the ECM. The extraction protocol involves the treatment of the skin model by pepsin and elastase. The concentration of the protein fragments released by the extraction was measured by ELISA and correlated directly to the collagen content.
  • Extraction Protocol
  • A) Pepsin Digestion
      • 1. Cut out the membrane with the epidermis (henceforth called EST) from the insert.
      • 2. Incubate EST in H2O bidest (0.5 mL) in a 2.0 mL cup over night at 4° C.
      • 3. Centrifuge at 10.000 rpm and 4° C. (Biofuge fresco, Heracus) for 3 min.
      • 4. Transfer EST into 0.1 mL pepsin buffer (0.1 mg/mL in 0.05 M acetic acid).
      • 5. Incubate over night at 4° C. with careful shaking.
      • 6. Centrifuge at 10.000 rpm and 4° C. (Biofuge fresco, Heracus) for 3 min.
      • 7. Transfer supernatant into a collection tube containing 0.1 mL buffered normal goat sera.
  • B) Elastase Digestion
      • 1. incubate EST in 0.1 mL elastase buffer (0.1 mg/mL in 0.1 M Tris-0.15 M NaCl-5 mM CaCl2 pH 7.8)
      • 2. Incubate overnight at 4° C. with careful shaking.
      • 3. Centrifuge at 10.000 rpm and 4° C. (Biofuge fresco, Heraeus) for 3 min.
      • 4. Combine the supernatant into the collection tube from step 7 pepsin digestion.
  • C) Neutralisation
  • The pH in the combined supernatant in the collection tubes are neutralised by adding 1 M Tris buffer (1/50 of the volume of the supernatants).
  • D) Collagen ELISA
  • The above described collagen extraction protocol is adapted from the collagen I extraction protocol described in the manual of the collagen I detection kit (Chondrex Inc. #6008).
  • The determination of collagen I was performed following the protocol given by the producer of the collagen I detection kit (Chondrex Inc. #6008).
  • Gene Expression Analyses
  • The expression of the genes coding for collagen I was analysed by RT-PCR (reverse transcriptase polymerase chain reaction) using the Taqman gene expression assays (Applied Biosystems). The ESTs were cut from the inserts as described above. The cut ESTs were stored in RNAlater (Ambion) at 4° C. until RNA preparation. For RNA preparation the tissue was disintegrated using the Precellys (Peqlab Biotechnologie GmbH, Germany). The cells were lysed in RLT buffer (RNeasy-kit, Qiagen). The RNA was purified from these lysates by three different protocols:
      • 1. RNeasy (Qiagen)
      • 2. Trizol extraction (Invitrogen, standard phenol extraction protocol)
      • 3. Chloroform extraction (standard protocol)
  • From the untreated EST-1000 sufficient RNA could be isolated with all three methods. The RNeasy method failed in both samples to purify RNA from ESTs treated with the test formulation. The same result was obtained using the Trizol protocol. Using the chloroform extraction (standard molecular biology protocol), RNA could be isolated also from the treated ESTs).
  • Consequently, all RNAs analysed by RT-PCR were purified by chloroform extraction.
  • Results
  • The expression of the collagen I gene was induced by all treatments (see FIG. 2). In particular, a relatively high fold change was observed for Echium oil in combination with Calendula oil and for Echium oil in combination with pomegranate seed oil.
  • E] Effect of Echium Oil and Calendula Oil Containing Products on Gene Expression in the EST 1000™ Skin Model
    • SUMMARY
  • Eight test oils containing Echium oil and Calendula oil, 2 commercially available cosmetic lotions(1) and 2 experimental lotions(2) were evaluated in the EST 1000™skin model(3). The test oil used was glyceryl tricaprylate/caprate (Crodamol GTCC, or MCI) to act as an inert carrier oil. The overall objective was to confirm earlier results showing that Echium/Calendula oil mixtures were synergistic in promoting collagen synthesis in skin. A number of genes involved in collagen synthesis in skin cells were analyzed using the reverse transcription-polymerase chain reaction (RT-PCR).
  • Notes
      • 1. The commercially available cosmetic lotions were; “Protect and Perfect Intense Beauty Serum” (The Boots Company PLC, Nottingham England) and “Advanced Night Repair Concentrate” (Estee Lauder DIST., New York N.Y., USA). Both products carry “moisturization” or “skin repair” claims and are brand leaders.
      • 2. Experimental lotions were fully formulated products (Formula 1 Cosmetic Developments Company Ltd., West Sussex UK) containing either Echium oil alone or a mixture of Echium oil plus Calendula oil.
      • 3. The EST 1000™ skin model is a 3-dimensional differentiated skin-cell model or “living skin equivalent”.
  • Formulations
  • The experimental lotions (referred to as Seeds #2 and Seeds #3 in Table III below) have the following composition:
  • Seeds #2
  • INCI NAME Sum Of INCI FORMULA
    AQUA 75.147
    CAPRYLIC/CAPRIC TRIGLYCERIDE 10
    ECHIUM PLANTAGINEUM OIL 5
    C12-16 ALCOHOLS 2.48
    CETEARYL ALCOHOL 1.5
    GLYCERIN 0.9
    PALMITIC ACID 0.76
    LECITHIN 0.76
    SORBITOL 0.75
    PHENOXYETHANOL 0.592
    SODIUM PCA 0.54
    INULIN LAURYL CARBAMATE 0.5
    XANTHAN GUM 0.3
    SCLEROTIUM GUM 0.3
    SODIUM LACTATE 0.21
    BENZOIC ACID 0.096
    SODIUM HYALURONATE 0.06
    DEHYDROACETIC ACID 0.056
    PHYTIC ACID 0.025
    ETHYLHEXYLGLYCERIN 0.016
    POLYAMINOPROPYL BIGUANIDE 0.008
  • Seeds #3
  • INCI NAME Sum Of INCI FORMULA
    AQUA 75.147
    CAPRYLIC/CAPRIC TRIGLYCERIDE 10
    ECHIUM PLANTAGINEUM OIL 4.95
    C12-16 ALCOHOLS 2.48
    CETEARYL ALCOHOL 1.5
    GLYCERIN 0.9
    LECITHIN 0.76
    PALMITIC ACID 0.76
    SORBITOL 0.75
    PHENOXYETHANOL 0.592
    SODIUM PCA 0.54
    INULIN LAURYL CARBAMATE 0.5
    XANTHAN GUM 0.3
    SCLEROTIUM GUM 0.3
    SODIUM LACTATE 0.21
    BENZOIC ACID 0.096
    SODIUM HYALURONATE 0.06
    DEHYDROACETIC ACID 0.056
    CALENDULA OFFICINALIS OIL 0.05
    PHYTIC ACID 0.025
    ETHYLHEXYLGLYCERIN 0.016
    POLYAMINOPROPYL BIGUANIDE 0.008
  • Protocol
  • Treatment Scheme of EST1000
  • Viability Test
  • 20 μL of the test oils were applied on the surface of the EST1000 in triplicates. After application the ESTs were incubated over night (18 h) at 37° C., 5% CO2 and 100% humidity. The visibility of EST1000 was measure by MTT-test.
  • Gene Expression Analyses:
  • 201 μL of the test oils were applied on the surface of the EST1000 in triplicates. After application the ESTs were incubated over night (18 h) at 37° C., 5% CO2 and 100% humidity. The epidermis was cut out of the insert and the tissues were fixed in RNAlater (Ambion) for RNA preparation. The RNA was prepared and the concentration and quality of the isolated RNA was controlled. The quality is determined by the ratio between the optical densities of the RNA at 260 and 280 nm. A ratio of more or equal 1.8 represents a good quality of RNA.
  • The gene expression of the three genes of interest (Col1A1, Col3A1, Col4A6) was analysed by quantitative real-time RT-PCR (Taqman).
  • MTT-Test
  • The viability of EST1000 was measured by the MTT-test which is based on the reduction of 3-4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid (MTT) by the mitochondrial reductases. The reduction of MTT leads to the formation of purple formazan crystals which are solved in isopropanol. The amount of formazan can be measured at 550 nm and correlates directly with the viability. The viability of the treated epidermis models is calculated as percentage of the non treated controls which are defined as 100%.
  • RT-PCR
  • The RT-PCR analyses were performed according to the Applied Biosystems protocol (Taqman). In short: 1 μg of the RNA was transcribed to cDNA which was used as template for the real-time RT-PCR with gene specific primers and probes.
  • Results
  • The master results are shown in Table III below and then separated out in the following Tables. A marked synergism, with respect to the expression of collagen1, collagen 3 and collagen 4 genes was observed, using the Echium oil and Calendula oil “model compound” mixtures. This result was also observed in the fully formulated experimental lotions.
  • TABLE III
    Echium Calendula
    oil (%) oil (%) Collagen 1 Collagen 3 Collagen 4
    Carrier oil
    MCT
    0 0 −10.6 9.5 0.9
    MCT 0 0.05 −8.2 −37.4 6.7
    MCT 0 5.0 −6.8 55.7 3.2
    MCT 5.0 0 3.0 −3.26 −1.8
    MCT 4.95 0.05 23.5 609.4 6.6
    Product
    Estee
    0 0 −32.5 −8.2 −60.9
    Lauder
    Boots No. 7 0 0 −19.5 7.1 2.6
    Seeds #2 5 0 20.9 423.8 −2.1
    Seeds #3 4.95 0.05 38.8 693.3 7.2
  • Genes
      • Collagen 1A1 gene encodes the most abundant protein in skin, tendon and bone, it is the end product when tissue heals by repair.
      • Collagen 3A1 produced in young fibroblasts before the production of stronger type 1 collagen.
      • Collagen 4A6 the key protein in basal lamina. The gene encodes one of the six subunits of type 4 collagen.
  • E1] Effect of Oils in MCT Carrier Oil on Change of Collagen 1 and Collagen 4 Gene Expression
  • Four oils were evaluated: the carrier oil (Crodamol GTCC) alone, carrier oil containing Calendula oil (0.05%), carrier oil containing Echium oil (5%), carrier oil containing Echium oil (4.95%) and Calendula oil (0.05%). The results are shown in Table IV below and graphically in FIG. 3.
  • TABLE IV
    Effect of oils in MCT carrier oil on collagen 1
    and collagen 4 gene expression
    Collagen
    1 Collagen 4
    Oil Change (%) from Change (%) from
    number Oil untreated control untreated control
    1 MCT oil alone −10.6 0.9
    2 MCT oil + Calendula −8.2 6.7
    oil (0.05%)
    3 MCT oil + Calendula −6.8 3.2
    oil (5%)
    4 MCT oil + Echium oil 3.0 −1.8
    (5%)
    5 MCT oil + Echium oil 23.5 6.6
    (4.95%) + Calendula
    oil (0.05%)
  • E2] the Effect of Applied Commercial Products on Collagens 1, 3 and 4 Gene Expression in the EST1 000™ Skin Model
  • Two commercially available skin-care products Estee Lauder's “Advanced Night Repair Concentrate” and “No7 Protect & Perfect Intense Beauty Serum” from the Boots Company. Two experimental, fully formulated, lotions were tested;
  • Seeds #2 containing Echium oil as the bioactive lipid and Seeds #3 containing Echium oil
  • (4.95%) and Calendula oil (0.05%). The results from these tests on Collagens 1 and 4 are shown Table V below and graphically in FIG. 4:
  • TABLE V
    Effect of formulated products on Collagen 1 and
    Collagen 4 gene expression
    Collagen
    1
    Change (%) Collagen 4
    From untreated Change (%) from
    Number Product control untreated control
    1 Estee Lauder −32.5 −60.9
    2 Boots No. 7 −19.5 2.6
    3 Seeds #2 20.9 −2.1
    (containing Echium oil
    5%)
    4 Seeds #3 38.8 7.2
    (containing Echium oil
    4.95% plus Calendula
    oil 0.05%)
  • The results of the above tests on Collagen 3 are shown in Table VI below and graphically in FIG. 5:
  • TABLE VI
    Effect of formulated products on Collagen 3 gene expression
    Collagen
    3 Change (%)
    Oil number Product from untreated control
    1 Estee Lauder −8.23
    2 Boots No. 7 7.09
    3 Seeds #2 423.75
    Containing Echium oil
    (5%)
    4 Seeds #3 693.25
    Containing Echium oil
    (5%) plus Calendula oil
    (0.05%)

Claims (16)

1.-15. (canceled)
16. A composition for topical application to the human or animal body comprising stearidonic acid which is provided by oil extracted from the seeds of the Boraginacae family, or an ester thereof, and an additional lipid which is a conjugated octadecatrienoic acid or an ester thereof which enhances the pro-collagen effects of stearidonic acid.
17. A composition as claimed in claim 16, wherein said additional lipid is calendic acid, catalpic acid, α-eleostearic acid, jacaric acid, punicic acid, esters of any of the foregoing acids, or any combination of the foregoing.
18. A composition as claimed in claim 17, wherein said acids are extracted from Calendula officinalis, Catalpa ovata, Aleurites fordii, Jacaranda mimosifolia and Punica granatum respectively.
19. A composition as claimed in claim 16, wherein the amount of said oil is from 0.1% to 10% w/w.
20. A composition as claimed in claim 16, additionally comprising a physiologically acceptable carrier.
21. A composition as claimed in claim 16, wherein the amount of said additional lipid is from 0.005 to 1% w/w.
22. A composition as claimed in claim 16 for use in a method of therapy practiced on the human or animal body.
23. A composition as claimed in claim 16 for use in a method of reducing visible signs of aging of human or animal skin.
24. A composition as claimed in claim 16 for use in a method of wound healing.
25. A method of reducing visible signs of aging of human or animal skin comprising applying to said skin either a composition comprising Echium oil or a composition as claimed in claim 16 in combination with a physiologically acceptable carrier.
26. A method of healing wounds in a human or animal body comprising applying to the locus of the wound either a composition comprising Echium oil or a composition as claimed in claim 16 in combination with a physiologically acceptable carrier.
27. A method of reducing trans-epidermal water loss comprising applying to the locus of the wound either a composition comprising Echium oil or a composition as claimed in claim 16 in combination with a physiologically acceptable carrier.
28. A composition comprising Echium oil or calendula oil or a mixture thereof for use in the stimulation of collagen synthesis in skin cells.
29. A composition comprising Echium oil for use in the reduction of trans-epidermal water loss.
30. A composition comprising Echium oil for use in the reduction of skin wrinkles.
US15/222,773 2009-02-06 2016-07-28 Composition for Treatment of Skin Abandoned US20170172964A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/222,773 US20170172964A1 (en) 2009-02-06 2016-07-28 Composition for Treatment of Skin

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0902040.5 2009-02-06
GBGB0902040.5A GB0902040D0 (en) 2009-02-06 2009-02-06 Composition for treatment of skin
PCT/GB2010/000215 WO2010089566A2 (en) 2009-02-06 2010-02-05 Composition for treatment of skin
US201113147248A 2011-08-19 2011-08-19
US15/222,773 US20170172964A1 (en) 2009-02-06 2016-07-28 Composition for Treatment of Skin

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US13/147,248 Continuation US9403042B2 (en) 2009-02-06 2010-02-05 Composition for treatment of skin
PCT/GB2010/000215 Continuation WO2010089566A2 (en) 2009-02-06 2010-02-05 Composition for treatment of skin

Publications (1)

Publication Number Publication Date
US20170172964A1 true US20170172964A1 (en) 2017-06-22

Family

ID=40469750

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/147,248 Active 2031-03-24 US9403042B2 (en) 2009-02-06 2010-02-05 Composition for treatment of skin
US15/222,773 Abandoned US20170172964A1 (en) 2009-02-06 2016-07-28 Composition for Treatment of Skin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/147,248 Active 2031-03-24 US9403042B2 (en) 2009-02-06 2010-02-05 Composition for treatment of skin

Country Status (5)

Country Link
US (2) US9403042B2 (en)
EP (1) EP2393557A2 (en)
CN (1) CN102307624A (en)
GB (1) GB0902040D0 (en)
WO (1) WO2010089566A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10966948B2 (en) 2019-07-23 2021-04-06 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
US11197841B2 (en) 2019-07-23 2021-12-14 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
US11931331B2 (en) 2018-07-27 2024-03-19 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
US11969454B2 (en) 2020-11-16 2024-04-30 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0814105D0 (en) 2008-08-01 2008-09-10 Springdale Sustainable Develop Composition for accelerated production of collagen
GB201010638D0 (en) 2010-06-24 2010-08-11 Seeds Lp Composition for treatment of skin
WO2013180490A1 (en) * 2012-05-30 2013-12-05 한국생명공학연구원 Pharmaceutical composition for preventing and alleviating skin aging, containing aleurites fordii extract, fraction thereof or diterpene compound isolated therefrom as active ingredient
EP4248981A3 (en) * 2014-10-31 2023-10-04 Pomega, Inc. Formulations containing pomegranate seed oil, rosa canina fruit oil and inula viscosa oleoresin or extract
TWI615141B (en) * 2016-06-23 2018-02-21 中國醫藥大學 Use of α-eleostearic acid for anti-aging
US10617613B2 (en) * 2018-04-30 2020-04-14 L'oreal Leave-on hair styling compositions and methods of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9012651D0 (en) 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
DE69724629T2 (en) 1996-06-03 2004-07-29 Croda International Plc., Goole COMPOSITIONS AND THEIR USE
US6340485B1 (en) 1996-06-03 2002-01-22 Croda International Plc Compositions and uses thereof
JP2001253817A (en) 2000-03-10 2001-09-18 Nagase & Co Ltd Collagen synthesis promoter and method for producing the same and skin care preparation containing the same
AU2002212256A1 (en) * 2000-09-20 2002-04-02 Basf Aktiengesellschaft Method for producing glycerides of conjugated, polyunsaturated fatty acids on the basis of their alkyl esters
EP1392278A4 (en) 2001-05-14 2005-05-04 Martek Biosciences Corp Production and use of a polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes
PL355298A1 (en) 2002-08-01 2004-02-09 DERMAPHYT Sp.z o.o. Dermatological preparation for curing skin defects
US20040161435A1 (en) 2003-02-14 2004-08-19 Gupta Shyam K. Skin Firming Anti-Aging Cosmetic Mask Compositions
FR2873295B1 (en) * 2004-07-26 2006-12-01 Expanscience Sa Lab USE OF AT LEAST ONE CONJUGATED FATTY ACID TRIENE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF INFLAMMATION
WO2007004229A2 (en) * 2005-07-06 2007-01-11 Rimonest Ltd. Methods of using pomegranate fractions for skin repair
US20070150773A1 (en) 2005-12-19 2007-06-28 Nortel Networks Limited Extensions to SIP signaling to indicate SPAM
US20070280898A1 (en) * 2006-06-06 2007-12-06 P & H Enterprises Of Marco Inc. Dermatological compositions
FR2902334B1 (en) 2006-06-16 2011-09-30 Nuxe Lab USE OF A SOURCE EXTRACT IN A COSMETIC COMPOSITION.
FR2903014B1 (en) 2006-06-30 2008-09-26 Occitane L COSMETIC COMPOSITION BASED ON POLYUNSATURATED FATTY ACIDS AND USES THEREOF
US20080213357A1 (en) 2007-02-12 2008-09-04 Andrew Bruce Hebard Plant Derived Lipid Useful for Nutraceutical and Cosemeceutical Applications
GB0814105D0 (en) * 2008-08-01 2008-09-10 Springdale Sustainable Develop Composition for accelerated production of collagen

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806327B2 (en) 2018-07-27 2023-11-07 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
US11931331B2 (en) 2018-07-27 2024-03-19 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
US10966948B2 (en) 2019-07-23 2021-04-06 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
US11197841B2 (en) 2019-07-23 2021-12-14 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
US11969454B2 (en) 2020-11-16 2024-04-30 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye

Also Published As

Publication number Publication date
WO2010089566A3 (en) 2011-03-31
WO2010089566A2 (en) 2010-08-12
GB0902040D0 (en) 2009-03-11
EP2393557A2 (en) 2011-12-14
CN102307624A (en) 2012-01-04
US20110293751A1 (en) 2011-12-01
US9403042B2 (en) 2016-08-02
WO2010089566A4 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
US20170172964A1 (en) Composition for Treatment of Skin
CN111700853B (en) Cosmetic composition with anti-allergy repairing effect and application thereof
KR101490762B1 (en) Cosmetic composition comprising the polysaccharide of Hibiscus esculentus as active ingredient
JP7309620B2 (en) Use of an extract of pericarp of NEPHELIUM LAPPACEUM for hydrating skin and/or mucous membranes
KR101352363B1 (en) Composition of skin external application for moisturizing comprising Scrophularia buergeriana Miq. extract
JP2013502380A (en) Skin refining complex, use of said complex, cosmetic or pharmaceutical composition comprising said complex and method for its application
WO2015157692A1 (en) Skin care composition comprising plant extracts
FR2755367A1 (en) USE OF AN ERECTA POTENTIAL EXTRACT IN THE FIELD OF COSMETICS AND PHARMACY, ESPECIALLY DERMATOLOGY
JP2004091376A (en) Epidermis keratinization normalizing agent and skin care preparation for external use for skin containing the same
WO2001066067A1 (en) Method of treating skin conditions
KR20130031988A (en) Skin external composition containing floral ginsenoside
KR20180082177A (en) Cosmetic composition comprising saccharomyces ferment filtrate, asparagus officinalis stem extract and tussilago farfara flower extract
KR100638053B1 (en) Cosmetic composition for abirritating skin containing extract of rumex crispus as active ingredient
KR20070007378A (en) Topical regulation of triglyceride metabolism
KR100678864B1 (en) Cosmetic composition for skin whitening comprising cnidium officinale extract and carnitine as active ingredient
US20150104426A1 (en) Skin-care agent containing pleurotus ferulae fruit body extract or pleurotus ferulae mycelium extract
US20230270660A1 (en) Silybum marianum (L.) Gaertn. oil for reinforcing the barrier function of the skin
KR101418979B1 (en) Compositions for promotion of collagen synthesis and cosmetics using the same
KR20180101125A (en) Cosmetic composition for skin whitening and improving skin wrinkle comprising horse oil and Rumex acetosella L. extracts
EP1633314A1 (en) Topical agents containing phytanic acid or a derivative thereof
KR101322850B1 (en) The cosmetic composition for pore-minimizing and inhibition of Sebum Secretion containing the extract of leaves of Mentha arvensis var. piperascens, wheat bud, and Platycodon grandiflorum
JP4488933B2 (en) Wrinkle improving agent and external composition for skin
KR20160000318A (en) Cosmetic composition containing Fir tree oil
JP2000143527A (en) Hyaluronic acid production promoter and skin preparation for external use containing the same
JP2014062090A (en) Transglutaminase activator

Legal Events

Date Code Title Description
AS Assignment

Owner name: SEEDS GROUP, LP, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:COUPLAND, KEITH;REEL/FRAME:039846/0485

Effective date: 20110802

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION